Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0P4GI
|
||||
Former ID |
DNC006273
|
||||
Drug Name |
C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C46H59N11O7
|
||||
Canonical SMILES |
CCCCC1C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CCC(=<br />O)N1)C(=O)N)CC3=CNC4=CC=CC=C43)CCCN=C(N)N)CC5=CC6=CC=CC<br />=C6C=C5
|
||||
InChI |
1S/C46H59N11O7/c1-2-3-13-35-45(64)57-22-9-16-38(57)44(63)56-36(24-27-17-18-28-10-4-5-11-29(28)23-27)42(61)54-34(15-8-21-50-46(48)49)41(60)55-37(25-30-26-51-32-14-7-6-12-31(30)32)43(62)53-33(40(47)59)19-20-39(58)52-35/h4-7,10-12,14,17-18,23,26,33-38,51H,2-3,8-9,13,15-16,19-22,24-25H2,1H3,(H2,47,59)(H,52,58)(H,53,62)(H,54,61)(H,55,60)(H,56,63)(H4,48,49,50)/t33-,34-,35-,36+,37-,38-/m0/s1
|
||||
InChIKey |
QQCJWXXVYXUARZ-ZPRVLUMXSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Melanocortin receptor | Target Info | Inhibitor | [1] | |
Melanocortin-3 receptor | Target Info | Inhibitor | [1] | ||
Melanocortin-4 receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | ||||
Pathway Interaction Database | Syndecan-3-mediated signaling events | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (s) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
G alpha (s) signalling events | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | J Med Chem. 2006 Mar 23;49(6):1946-52.Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.